Tim A. Ahles, PhD, on Neurocognitive Late Effects
2016 Cancer Survivorship SymposiumTim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Dana Barnea, MD, of Memorial Sloan Kettering Cancer Center, discusses data that suggest annual palpation of the thyroid is an adequate and safe means of screening childhood and young adult cancer survivors, a population at high risk for this type of cancer (Abstract 254).
Jennifer A. Ligibel, MD, of the Dana-Farber Cancer Institute, discusses the physical activity behaviors and weight changes in a study cohort of young women with breast cancer (Abstract 166).
Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham, discusses long-term and late effects experienced by cancer survivors.
Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative programs to prevent falls and injuries (Abstract 130).